NEWS
FOR IMMEDIATE RELEASE Contacts: Molly Ingraham
Thursday, November 15, 2007 858-551-6677
or
Nicole Beckstrand
858-456-8881
TWO NEW MEMBERS ELECTED TO CALIFORNIA HEALTHCARE INSTITUTE’S
BOARD OF DIRECTORS
LA JOLLA, CALIF., Nov. 15, 2007 -- The California Healthcare Institute (CHI) today announced the election of Scott Garrett, president and CEO of Beckman Coulter, Inc., and George A. Scangos, Ph.D., president and chief executive officer of Exelixis, to its board of directors. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.
Scott Garrett is president and chief executive officer of Beckman Coulter, Inc., which develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests, helping to improve patient health and reduce the cost of care. Before joining Beckman Coulter in 2002, Garrett served as chief executive officer of Garrett Capital Advisors, LLC – a company he founded in 1998. Prior to that, he spent 25 years working for Baxter International and American Hospital Supply Corporation in a wide range of medical device and life sciences areas. In 1994, Garrett led the buyout of Baxter’s diagnostics business. As chairman and chief executive officer, he built Baxter spin-off, Dade Behring, into one of the world’s largest clinical diagnostics companies. Garrett serves on the board of directors for AdvaMed. He is a member of the executive advisory council of Water Street Healthcare Partners, L.P. and the advisory board of Radius Ventures, LLC. He holds a Bachelor of Science degree in mechanical engineering from Valparaiso University and a Master of Business Administration from Lake Forest Graduate School of Management.
George A. Scangos, Ph.D., is president and chief executive officer of Exelixis, a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Scangos began his career on the faculty of the Johns Hopkins University, where he now holds an appointment as adjunct professor of biology. He left Hopkins in 1986 to work for Bayer Corporation, where he held several positions, including senior vice president of research and development for Bayer's pharmaceutical division, and then president of Bayer Biotechnology. Scangos serves on the boards of directors of Anadys Pharmaceuticals, Entelos, Inc., as well as Exelixis. He serves on the board of visitors at the University of California, San Francisco School of Pharmacy, the board of overseers at the University of California, Davis Medical School, and the advisory board for the Cornell University Life Sciences Initiative. Scangos received a Bachelor of Arts degree from Cornell University, a doctorate in microbiology from the University of Massachusetts, and was a Jane Coffin Childs Postdoctoral Fellow in the laboratory of Frank Ruddle at Yale University.
“As we work to advance medical innovation through responsible public policy, we strive to bring together our industry’s top leaders to help guide the organization,” said David Gollaher, Ph.D., CHI’s president and chief executive officer. “Beckman Coulter and Exelixis are at the leading edge of life sciences R&D, and we are pleased to welcome George and Scott to our board.”
CHI represents more than 250 leading medical device, biotechnology, diagnostics and pharmaceutical companies and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is www.chi.org.
###